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The biosynthesis and post-translational processing of sucrase-isomaltase and dipeptidylpeptidase IV were 
studied by L-[3sS]methionine labeling, immunoisolation with monoclonal antibodies and SDS-PAGE in 
post-confluent Caco-2 cells treated with monensin (10 PM, 48 h). In addition to its classical effect on the 
post-translational processing of both hydrolases, i.e. an inhibition of the conversion of the high-mannose 
to the complex glycosylated form of the enzymes, monensin was found to have two other effects: a marked 
decrease of sucrase-isomaltase expression, but not of dipeptidylpeptidase IV; an increased turnover of 
glucose, as substantiated by increased rates of glucose consumption and lactic acid production and a 
decreased glycogen content. Whether these two effects are related to the particular differentiation and meta- 
bolic status of Caco-2 cells is discussed, as well as a possible role for the drug-induced modifications of 
glucose turnover on the decreased expression of sucrase-isomaltase. 
Monensin Microvillar hydrolase Protein glycosylation Glucose consumption Glycolysis Glycogen 
(Caco-2 cell) 
1. INTRODUCTION 
Human colon cancer cell lines HT-29 and 
Caco-2 have been shown to undergo enterocytic 
differentiation in culture [1,2], the pattern of 
which is not of small-intestinal, but of the fetal col- 
on type [3,4]. As in most malignant epithelial cells 
their turnover of glucose is different from that 
found in the normal, with the rates of glucose con- 
sumption and lactic acid production being much 
higher [5], and with glycogen being stored at high 
levels [6], a particularity also shared by human 
fetal colon cells [7] but absent from the normal 
post-natal colon [7]. It has been shown that the ex- 
pression of microvillar hydrolases, and more par- 
ticularly that of sucrase-isomaltase, could be 
modulated in these cells by imposing on them per- 
manent modifications of their utilization of 
glucose, either by modifying the hexose composi- 
tion of the culture medium, as in HT-29 cells 
[1,8,9], or in the case of Caco-2 cells by inducing 
permanent glycogenolysis [lo]. These observations 
suggested that, at least in these cells, the regulation 
of the expression of sucrase-isomaltase was depen- 
dent, in part, on the turnover of glucose, the 
mechanism of this regulation still remaining 
unknown. Here, we compared the effect of 
monensin on the biosynthesis of sucrase- 
isomaltase and dipeptidylpeptidase IV in Caco-2 
cells. Monensin, an ionophore which binds 
monovalent cations, has been shown in a variety of 
systems to block the processing of newly synthe- 
sized glycoproteins at the site of the Golgi complex 
[ 1 l-l 51. In normal small intestinal [ 161 and kidney 
cells [17] it inhibits the conversion of the high- 
mannose to the complex form of microvillar 
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hydrolases. We show here that treatment of 
Caco-2 cells with monensin results not only in 
modifications of the post-translational processing 
of the enzymes, as would be expected, but also, 
unexpectedly, in a specific decrease in expression 
of sucrase-isomaltase and in marked modifications 
of the turnover of glucose. 
2. MATERIALS AND METHODS 
Caco-2 cells, obtained from J. Fogh (Memorial 
Sloan Kettering Cancer Center, Rye, NY) were 
cultured in 25 cm’ Corning plastic flasks in 
Dulbecco’s modified Eagle’s minimum essential 
medium (containing 25 mM glucose) sup- 
plemented with 20% inactivated (56”C, 30 min) 
fetal bovine serum and 1% non-essential amino 
acids as described in [lo]. Monensin (Calbiochem 
Behring, La Jolla) was added to the culture 
medium of stationary cultures (i.e. when Caco-2 
cells are fully differentiated [l,lO]) for two con- 
secutive periods of 24 h. For biosynthesis studies 
Caco-2 cells (passages 70-75) were harvested after 
3 h exposure to 500 ,&i L-[35S]methionine (Amer- 
sham) in 2 ml methionine-free culture medium. 
Preparation of cell homogenates and brush 
border-enriched fractions (P2) was as in [lo]. Im- 
munoprecipitates, treatment with endo+- 
acetylglucosaminidase H (Endo-H, Miles), SDS- 
PAGE and autoradiography were performed as in 
1181, using monoclonal antibodies HBB2/614/88 
[18] for sucrase-isomaltase and HBB3/775/42 [18] 
for dipeptidylpeptidase IV (obtained from H.P. 
Hauri, Biocenter of the University of Basel, Basel). 
Glucose and lactic acid concentration in the 
medium and intracellular concentration of 
glycogen were measured as in [5]. The rates of 
glucose consumption and lactic acid production 
were calculated from the results obtained within 
the first 8 h after the medium change, i.e. when 
they are linear (see fig.3). Intracellular glycogen 
was measured after 48 h of treatment. Proteins 
were measured as in [ 191. 
3. RESULTS 
To determine the maximum concentration of the 
drug compatible with an absence of effect on cell 
viability, exponentially growing (day 4-5) and sta- 
tionary cultures (day 14-15) were treated for 48 h 
with various concentrations of monensin. The op- 
timal concentration was found to be 10 PM. In ex- 
ponential cultures this concentration did not 
modify the doubling time of the cells; in stationary 
cultures it had no effect on cell viability as assessed 
by trypan blue exclusion, total cell number and 
total protein content per flask. The phase-contrast 
morphology of the cells was not modified, except 
for a marked augmentation of the size of domes 
(which are a typical feature of post-confluent 
Caco-2 cells [2] and are indicative of active 
transepithelial ion transport properties [20]). 
The effect of monensin on the biosynthesis and 
post-translational processing of sucrase-isomaltase 
and dipeptidylpeptidase IV was studied on day 16, 
i.e. when the rate of synthesis of the enzymes is 
maximum. Identification of the high-mannose 
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Fig. 1. Fluorograms of SDS-PAGE of sucrase-isomaltase 
(SU and dipeptidylpeptidase IV (DPP IV) 
immunoisolated with the corresponding monoclonal 
antibodies from the cell homogenates of untreated 
Caco-2 cells (day 16 in culture) labeled for 3 h with L- 
[35S]methionine. Immunoprecipitates were run on SDS- 
PAGE in the absence of (-) or after a treatment with 
Endo-H (+). The upper band of the enzymes 
(insensitive to Endo-H) corresponds to the complex 
glycosylated form and the lower band (sensitive to Endo- 
H) to the high-mannose form. 
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(sensitive to Endo-H treatment) and complex form 
of the enzymes (unsensitive to Endo-H) is as in- 
dicated in fig. 1. Treatment with monensin results 
in a double effect: (i) It inhibits the conversion 
from the high-mannose to the complex form of 
both sucrase-isomaltase and dipeptidylpeptidase 
IV; as shown in fig.2 only the high-mannose form 
of the enzymes could be detected in the cell 
homogenate, in contrast to control cells where 
both the high-mannose and complex forms of the 
enzymes are present. In the brush border-enriched 
fraction (P2) only the complex form of the en- 
zymes is present in control cells, whereas in 
monensin-treated cells only a faint band is detec- 
table; this band corresponds to the high-mannose 
form and the reason for its presence is most likely 
that the P2 fraction is not pure brush border mem- 
brane. (ii) The second effect is a marked decrease 
of the labeling of sucrase-isomaltase. As shown in 
fig.2 the intensity of labeling of sucrase-isomaltase 
in the cell homogenate from monensin-treated cells 
is much lower than the total labeling of the enzyme 
in control cells, in contrast to dipeptidylpeptidase 
IV which, although in different molecular forms, 
has the same intensity of labeling under both con- 
ditions. 
In the course of these studies we observed that 
treatment with monensin resulted in more rapid 
acidification of the culture medium as compared to 
control cells, suggesting a higher rate of produc- 
tion of lactic acid. This prompted us to investigate 
further a possible effect of monensin on glucose 
utilization. The results reported in table 1 show 
that treatment with monensin indeed results in a 
more than 2-fold increase of the rates of glucose 
consumption and lactic acid production and a 
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Fig.2. Fluorograms of SDS-PAGE of 
immunoprecipitates of L-[3sS]methionine-labeled 
sucrase-isomaltase (SI) and dipeptidylpeptidase IV 
(DPP IV) from the cell homogenate (H) and a brush 
border-enriched fraction (P2) of Caco-2 cells treated (+) 
or not treated (-) with monensin (10 ,uM, 48 h). For 
immunoprecipitation of the enzymes the same amount 
of cell proteins was used in both control and treated 
cells. Immunoprecipitates from the cell homogenates 
were done with the concomitant use of both anti SI and 
anti DPP IV monoclonal antibodies; single antibodies 
were used for the P2 fraction. The two bands of SI and 
DPP IV in the cell homogenate from control cells 
correspond for each enzyme to the high-mannose (lower 
bands) and complex form (upper band) of the enzymes 
(see fig. 1); in the P2 fraction from control cells only the 
complex form of the enzymes is present. Note the 
absence of complex form of the enzymes in monensin- 
treated cells. Also note the very low intensity of labeling 
of SI in monensin-treated cells as compared to the 
control. 
Table 1 
Effect of monensin on the rates of glucose consumption and lactic acid production and on the intracellular glycogen 
content in post-confluent Caco-2 cells 
Glucose consumption Lactic acid production Intracellular glycogen Proteins per 
(nmol/h per (nmol/h per (ug/mg protein) flask (mg) 
mg protein) mg protein) 
Control cells 393 * 19 668 + 32 265 + 15 5.46 f 0.22 
Monensin (10 FM) 842 + 12 1768 f 28 147-t 7 5.45 -t 0.21 
For details, see section 2. Caco-2 cells (passage 72) were treated with monensin between days 14 and 16 in culture; each 
value represents the mean and SE of 3-5 different flasks 
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Fig.3. Evolution of the concentration of glucose in the 
culture medium of Caco-2 cells (day 15) after a medium 
change. (0) Control cells; cells treated with monensin: 
(I) 0.5 ,uM, (0) 1 ,uM, (7) 5 ,uM, (A) 10 PM. Cells were 
cultured in 25 cm2 plastic flasks in the presence of 5 ml 
culture medium. 
nearly 50% decrease of glycogen accumulation, 
without modification of the cell protein content. 
The effect on the rate of glucose consumption is 
dose-dependent (fig.3) and is reproducible at each 
medium change (not shown). 
4. DISCUSSION 
Although Caco-2 cells are malignant colonic 
cells and therefore should not be considered a 
totally relevant ‘in vitro’ model for normal small 
intestinal cells, they have been shown to be an ap- 
propriate model for the study of the biosynthesis 
and intracellular transport of microvillar 
hydrolases [18]. The present results confirm the 
relevance of this model for such studies as far as 
treatment of the cells with monensin results in the 
same inhibition of the conversion of the enzymes 
from their high-mannose to their complex form as 
demonstrated for sucrase-isomaltase and dipep- 
tidylpeptidase IV in small intestinal cells [ 161 or for 
dipeptidylpeptidase IV in kidney cells [17]. 
In addition to this classical effect monensin, 
however, has two other effects in Caco-2 cells: one 
is a marked and specific decrease of the expression 
of sucrase-isomaltase which appears to be par- 
ticular to Caco-2 cells, as it has not been observed 
in normal intestinal cells [16]; whether this 
modification of sucrase-isomaltase expression 
results from decreased biosynthesis and/or in- 
creased degradation of the enzyme has to be 
documented further. The second effect is a marked 
increase in glucose turnover. This latter effect is 
not restricted to Caco-2 cells and is independent of 
the differentiation state of the cells as it has also 
been observed in a number of undifferentiated 
human colon carcinoma cell lines (unpublished), 
suggesting that it could be related to the particular 
metabolic status of malignant epithelial cells. 
The mechanism by which monensin interferes 
with the processing of membrane glycoproteins is 
far from being clear [l 11, as well as that responsi- 
ble for its particular additional effects in Caco-2 
cells. Whether there is a relationship in these cells 
between the monensin-dependent increase in 
glucose turnover and the specific inhibiting effect 
of the drug on sucrase-isomaltase expression is 
however questionable in regard to a number of 
observations. Indeed, previous studies have shown 
that increased glucose consumption, or decreased 
glycogen accumulation, or the association of both, 
are concomitant with decreased expression of 
sucrase-isomaltase but not, or to a much lesser ex- 
tent, of other hydrolases in situations such as 
Caco-2 cells treated with forskolin [lo], undif- 
ferentiated HT-29 cells grown in the presence of 
glucose [1,8,9] or the human fetal colon in the late 
stages of gestation [7,21]. 
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